Usefulness of the MASCC scale in the management of neutropenic fever induced by chemotherapy in patients with solid neoplasm;Utilidad de la escala de MASCC en el tratamiento de la neutropenia febril inducida por quimioterapia en pacientes con neoplasia sólida

Medicina Clinica

Volumn 133, Issue 8, 2009, Pages 296-299

  Gayol, María Del Carmen ^a   Font, Albert ^a   Casas, Irma ^a   Estrada, Oriol ^a   Domínguez, M Jesús ^a   Pedro Botet, M Luisa ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Neutropenicfever Chemotherapy Cancer MASCC

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; COST CONTROL; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTINATIONAL ASSOCIATION OF SUPPORT TREATMENT IN CANCER SCALE; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; EPIDEMIOLOGIC METHODS; FEMALE; FEVER; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; QUALITY OF LIFE;

EID: 68649118811     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2008.12.022     Document Type: Article

References (10)

1. E.J. Bow Management of the febrile neutropenic cancer patient: lessons from 40 years of study Clin Infect Dis 11 2005 24 29
2. E. Toussaint, E. Bahel-Ball, M. Vekemans, A. Georgala, L. Al-Hakak, and M. Paesmans Causes of fever in cancer patients (prospective study over 477 episodes) Support Care Cancer 14 2006 763 769
3. R. Ramphal Changes in the etiology of bacteremia in febile neutropenic patients and the susceptibilities of the currently isolated pathogens Clin Infect Dis 39 Suppl 1 2004 25
4. W. Kern Risk Assessment and Treatment of Low Risk Patients with Febrile Neutropenia Clin Infect Dis 42 2006 533 540
5. N. Sipsas, G. Bodey, and D. Kontoyiannis Perspectives for the management of febrile neutropenic patients with cancer in the 21st century Cancer 103 2005 1103 1113
6. J.A. Talcott, R. Finberg, R.B. Mayer, and L. Goldman The medical course of cancer patients with fever and neutropenia: clinical identification of low risk subgroup at presentation Arch Intern Med 148 1988 2561 2568
7. J. Klastersky, M. Paesmans, E.B. Rubenstein, M. Boyer, L. Elting, and R. Feld The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low- risk febrile neutropenic patients J Clin Oncol 18 2000 3038 3051
8. G. Chamilos, A. Bamias, E. Efstathiou, P. Zorzou, E. Kastritis, and E. Kostis Outpatients treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin Cancer 103 2005 2629 2635
9. A. Uys, B.L. Rapoport, and R. Anderson Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk index score Support Care Cancer 12 2004 555 560
10. J. Gaytán-Martínez, E. Mateos-Garcia, E. Sánchez-Cortés, J. González-Llavven, L.J. Casanova-Cardiel, and J.L. Fuentes-Allen Microbiological findings in febrile neutropenia Arch Med Res 31 2000 388 392